{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:15:58Z","timestamp":1791306958840,"version":"4.3.1"},"reference-count":79,"publisher":"Oxford University Press (OUP)","issue":"suppl_1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1,1]]},"DOI":"10.1093\/ndt\/gfw404","type":"journal-article","created":{"date-parts":[[2016,10,21]],"date-time":"2016-10-21T19:05:23Z","timestamp":1477076723000},"page":"i22-i29","source":"Crossref","is-referenced-by-count":45,"title":["Membranous nephropathy: thinking through the therapeutic options"],"prefix":"10.1093","volume":"32","author":[{"given":"Daniel","family":"Cattran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Brenchley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,1,20]]},"reference":[{"key":"key\n\t\t\t\t20171221053456_gfw404-B1","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/ndt\/gfq665","article-title":"The incidence of primary glomerulonephritis worldwide: a systematic review of the literature","volume":"26","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B2","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1523-1755.2004.00873.x","article-title":"Idiopathic membranous nephropathy: definition and relevance of a partial remission","volume":"66","year":"2004","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJM199307083290203","article-title":"Prognosis of untreated patients with idiopathic membranous nephropathy","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B4","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1681\/ASN.2009080861","article-title":"Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy","volume":"21","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B5","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.2215\/CJN.01330209","article-title":"The natural history of the non-nephrotic membranous nephropathy patient for the Metropolitan Toronto Glomerulonephritis Registry","volume":"4","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B6","first-page":"139","article-title":"KDIGO clinical practice guidelines for glomerulonephritis","volume":"S2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B7","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/modpathol.2012.207","article-title":"Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies","volume":"26","year":"2013","journal-title":"Mod Pathol"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B9","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1009742","article-title":"Risk HLA-DQA1 and PLA 2 R1 alleles in idiopathic membranous nephropathy","volume":"364","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B10","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/ki.2012.209","article-title":"Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy","volume":"82","year":"2012","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/1354750X.2014.993708","article-title":"Prognostic value of the dynamics of M-type phospholipase A2 receptor antibody titers in patients with idiopathic membranous nephropathy treated with two different immunosuppression regimens","volume":"20","year":"2015","journal-title":"Biomarkers"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B12","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1681\/ASN.2013040430","article-title":"Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy","volume":"25","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B13","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/S0272-6386(99)70138-1","article-title":"Prognosis after a complete remission in adult patients with idiopathic membranous nephropathy","volume":"33","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B14","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/ncpneph0915","article-title":"Remission of proteinuria in primary glomerulonephritis: we know the goal but do we know the price?","volume":"4","year":"2008","journal-title":"Nat Clin Pract Nephrol"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B15","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/ki.1992.374","article-title":"Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis","volume":"42","year":"1992","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B16","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/ki.1997.127","article-title":"Validation of a predictive model of idiopathic membranous nephropathy: Its clinical and research implications","volume":"51","year":"1997","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B17","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1681\/ASN.2013020185","article-title":"Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy","volume":"25","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0891-6632(91)90021-G","article-title":"Structural-functional relationships in type I insulin-dependent diabetes mellitus in humans","volume":"5","year":"1991","journal-title":"J Diabet Complications"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B19","first-page":"617","article-title":"Renal function and functional reserve in healthy elderly individuals","volume":"20","year":"2007","journal-title":"J Nephrol"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B20","first-page":"1137","article-title":"Combined assessment of phospholipase A2 receptor autoantibodies and glomerular deposits in membranous nephropathy","volume":"27","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B21","first-page":"1","article-title":"Spontaneous remission of proteinuria is a frequent event in phospholipase A 2 receptor antibody negative patients with membranous nephropathy","volume":"30","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B22","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B23","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMc1511702","article-title":"A mechanism for cancer-associated membranous nephropathy","volume":"374","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B24","article-title":"Long-term exposure to air pollution and increased risk of membranous nephropathy in China","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B25","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1093\/ndt\/gfv435","article-title":"Long-term outcomes of persistent disease and relapse in primary membranous nephropathy","volume":"31","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B26","article-title":"Complete and partial remission as surrogate end points in membranous nephropathy","volume":"26","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B27","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/S0140-6736(15)60731-0","article-title":"Pathophysiological advances in membranous nephropathy: time for a shift in patient\u2019s care","volume":"385","year":"2015","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B28","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.2215\/CJN.10471013","article-title":"Association of anti-PLA2R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy","volume":"9","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B29","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/ki.2012.486","article-title":"Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy","volume":"83","year":"2013","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B30","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/ajt.13133","article-title":"Anti-phospholipase A2 receptor antibodies in recurrent membranous nephropathy","volume":"15","year":"2015","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B31","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/ki.1995.453","article-title":"A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy","volume":"48","year":"1995","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B32","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1681\/ASN.2007020166","article-title":"A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy","volume":"18","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B33","first-page":"CD004293","article-title":"Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome","volume":"10","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B34","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.2215\/CJN.08880813","article-title":"Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy","volume":"9","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B35","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4103\/0971-4065.136884","article-title":"Study of hypothalamic pituitary adrenal axis in patients of membranous nephropathy receiving modified Ponticelli regimen","volume":"25","journal-title":"Indian J Nephrol"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B36","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1093\/ndt\/gfn350","article-title":"Introduction of a cyclophosphamide-based treatment strategy and the risk of ESRD in patients with idiopathic membranous nephropathy: a nationwide survey in the Netherlands","volume":"23","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B37","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1046\/j.1523-1755.2001.0590041484.x","article-title":"Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial","volume":"59","author":"for the North American Nephrotic Syndrome Study Group","year":"2001","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B38","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/sj.ki.5002215","article-title":"Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial","volume":"71","year":"2007","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B39","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0140-6736(12)61566-9","article-title":"Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial","volume":"381","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B40","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/MAJ.0b013e3181ca3a7d","article-title":"Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial","volume":"339","year":"2010","journal-title":"Am J Med Sci"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B41","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000348475","article-title":"Tacrolimus combined with corticosteroids in idiopathic membranous nephropathy: a randomized, prospective, controlled trial","volume":"181","year":"2013","journal-title":"Contrib Nephrol"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B42","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s11596-015-1480-8","article-title":"Efficacy and safety of tacrolimus vs. cyclophosphamide for idiopathic membranous nephropathy: a meta-analysis of Chinese adults","volume":"35","year":"2015","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B43","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/nep.12569","article-title":"Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: randomized control trial","volume":"21","year":"2016","journal-title":"Nephrology (Carlton)"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B44","first-page":"85","article-title":"Remissions and relapses in idiopathic membranous nephropathy","volume":"7 (Suppl 1)","year":"1992","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B45","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","article-title":"Rituximab for idiopathic membranous nephropathy","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B46","doi-asserted-by":"crossref","first-page":"e0122171","DOI":"10.1371\/journal.pone.0122171","article-title":"Prophylaxis and treatment of Pneumocystis Jiroveci pneumonia in lymphoma patients subjected to Rituximab-contained therapy: a systemic review and meta-analysis","volume":"10","year":"2015","journal-title":"PloS One"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B47","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1080\/14740338.2016.1198775","article-title":"Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA\u2019s adverse event reporting system","volume":"15","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B48","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/sj.ki.5002628","article-title":"Rituximab treatment of idiopathic membranous nephropathy","volume":"73","year":"2008","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B49","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.2215\/CJN.05080610","article-title":"Rituximab therapy in idiopathic membranous nephropathy: a 2-year study","volume":"5","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B50","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1681\/ASN.2012020181","article-title":"Rituximab in idiopathic membranous nephropathy","volume":"23","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B51","article-title":"Low-dose rituximab is poorly effective in patients with primary membranous nephropathy","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B52","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2215\/CJN.01180307","article-title":"Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy","volume":"2","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B53","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.autrev.2016.02.014","article-title":"New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: a prospective study and a review of the literature","volume":"15","year":"2016","journal-title":"Autoimmun Rev"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B54","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B55","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000430849","article-title":"A multicenter randomized controlled trial of Rituximab versus Cyclosporine in the treatment of idiopathic membranous nephropathy (MENTOR)","volume":"130","year":"2015","journal-title":"Nephron"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B56","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/ckj\/sfv075","article-title":"A European multicentre and open-label controlled randomized trial to evaluate the efficacy of Sequential treatment with TAcrolimus\u2013Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study","volume":"8","year":"2015","journal-title":"Clin Kidney J"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B57","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1053\/j.ackd.2011.06.008","article-title":"Historical aspects of proteinuria","volume":"18","year":"2011","journal-title":"Adv Chronic Kidney Dis"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B58","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1053\/j.ajkd.2005.10.016","article-title":"A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy","volume":"47","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B59","article-title":"Melanocortin 1 receptor agonist protects podocytes through catalase and rhoa activation","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B60","doi-asserted-by":"crossref","first-page":"e0142033","DOI":"10.1371\/journal.pone.0142033","article-title":"Synthetic ACTH in high risk patients with idiopathic membranous nephropathy: a prospective, open label cohort study","volume":"10","year":"2015","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B61","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/ndt\/gfu069","article-title":"A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar\u00ae Gel) in nephrotic syndrome due to idiopathic membranous nephropathy","volume":"29","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B62","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","article-title":"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis","volume":"365","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B63","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00007890-199701150-00008","article-title":"Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups","volume":"63","year":"1997","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B64","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1053\/j.ajkd.2008.04.013","article-title":"Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial","volume":"52","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B65","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1053\/j.ajkd.2007.05.015","article-title":"Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide","volume":"50","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B66"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B67","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/rheumatology\/keu452","article-title":"Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis","volume":"54","year":"2015","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B68","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40620-013-0028-x","article-title":"Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy","volume":"27","year":"2014","journal-title":"J Nephrol"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B69","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12882-015-0199-x","article-title":"Comparison of tripterygium wilfordii multiglycosides and tacrolimus in the treatment of idiopathic membranous nephropathy: a prospective cohort study","volume":"16","year":"2015","journal-title":"BMC Nephrol"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B70","first-page":"668","article-title":"Eculizamab in the treatment of idiopathic membranous nephropathy","volume":"13","year":"2002","journal-title":"Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B71","first-page":"157","article-title":"Alternative pathway dysregulation and the conundrum of complement activation by IgG4 immune complexes in membranous nephropathy","volume":"7","year":"2016","journal-title":"Front Immunol"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B72","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/eci.12545","article-title":"A new rescue regimen with plasma exchange and rituximab in high-risk membranous glomerulonephritis","volume":"45","year":"2015","journal-title":"Eur J Clin Invest"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B73","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2215\/CJN.11001210","article-title":"Have we changed the outcome in membranous nephropathy? A propensity study on the role of immunosuppressive therapy","volume":"6","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B74","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/ndt\/gfr220","article-title":"Idiopathic membranous nephropathy and nephrotic syndrome: Outcome in the era of evidence-based therapy","volume":"27","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B75","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM197912133012401","article-title":"A controlled study of short-term prednisone treatment in adults with membranous nephropathy. Collaborative Study of the Adult Idiopathic Nephrotic Syndrome","volume":"301","year":"1979","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B76","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10157-014-0993-y","article-title":"The influences of larger physical constitutions including obesity on the amount of urine protein excretion in primary glomerulonephritis: research of the Japan Renal Biopsy Registry","volume":"19","year":"2015","journal-title":"Clin Exp Nephrol"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B77","doi-asserted-by":"crossref","first-page":"e0156736","DOI":"10.1371\/journal.pone.0156736","article-title":"Regional variability of lifestyle factors and hypertension with prediabetes and newly diagnosed type 2 diabetes mellitus: the population-based KORA-F4 and SHIP-TREND studies in Germany","volume":"11","year":"2016","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B78","article-title":"Prevalence of diabetes mellitus and impaired glucose metabolism in the adult population of the Basque Country, Spain","year":"2016","journal-title":"Diabet Med"},{"key":"key\n\t\t\t\t20171221053456_gfw404-B79","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/sj.ki.5000289","article-title":"Renal pathology in idiopathic membranous nephropathy: a new perspective","volume":"69","year":"2006","journal-title":"Kidney Int"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/32\/suppl_1\/i22\/23000603\/gfw404.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T10:46:31Z","timestamp":1513853191000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/ndt\/article\/32\/suppl_1\/i22\/2930806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,1]]},"references-count":79,"journal-issue":{"issue":"suppl_1","published-online":{"date-parts":[[2017,1,20]]},"published-print":{"date-parts":[[2017,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfw404","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,1]]},"published":{"date-parts":[[2017,1,1]]}}}